New Delhi, Sep 6 (IANS) Prime Minister Narendra Modi on Monday said the local traditions should be used to help the vaccination drive. He was interacting with the healthcare workers and beneficiaries of the Covid vaccination programme in Himachal Pradesh via video conferencing.Addressing the gathering, Modi said that Himachal Pradesh has emerged as a champion in the fight against the largest epidemic in 100 years."Himachal has become the first state in India to have administered at least one dose of corona vaccine to each one of its entire eligible population which underlines the importance of 'Aatmvishwas' and 'Aatmnirbharta'," said Modi. While talking to Dr Rahul of Civil Hospital at Shimla, the prime Minister lauded the team effort for minimising the vaccine wastage. Talking to a vaccination beneficiary, Modi inquired about the facilities of vaccination and how they dealt with the rumours regarding vaccination. The Prime Minister spoke to ASHA worker Nirma Devi from Kullu, and enquired about her experience with the vaccination drive. The Prime Minister emphasised to use the local traditions in helping the vaccination drive in his virtual address. He praised the model of dialogue and collaboration developed by the team and asked about how the team travelled long distances to administer vaccines.The PM said that the world's biggest vaccination programme is continuing due to the efforts of people like Karmo Devi.Karmo Devi of Una has the distinction of vaccinating 22,500 people. He praised her spirit as she kept on working despite a fracture in her leg. Lauding the efforts of doctors, ASHA workers, Aanganwadi workers, medical personnel, teachers, and other staff in the vaccination drive against Covid, PM Modi said that the success of vaccination in India is the result of the spirit and hard work of its citizens. India is vaccinating at the record speed of 1.25 crore vaccines per day. This means that the number of vaccinations in India in one day is more than the population of many countries.Recalling the mantra 'Sabka Prayas' which Modi mentioned during his Independence Day speech, he said that this success is a manifestation of that. He praised the dialogue and collaboration model and expressed happiness that even in a remote district like Lahaul-Spiti, Himachal has been a leader in giving 100 per cent first dose."This is the area which used to be cut off from the rest of the country for months before the Atal Tunnel was built," said PM Modi, while admiring the state's efforts to not allow any rumour or disinformation to hamper the vaccination efforts. "Himachal is a proof of how the country's rural society is empowering the world's largest and fastest vaccination campaign," said PM Modi.Referring to recently notified Drones rules, PM Modi said that these rules will help in the spheres of many sectors like health and agriculture and will open doors for new possibilities. He inspired the farmers and gardeners of the state to make farming in Himachal complete organic within the next 25 years.--IANSavr/dpb/skp/
New Delhi, Aug 20 (IANS) Zydus Cadila's three-dose indigenous Covid-19 vaccine ZyCoV-D, the world's first DNA-based Covid vaccine that can be administered to people aged 12 and above, on Friday received emergency use authorisation (EUA) in India, an official statement said.The Central Drugs Standard Control Organisation's (CDSO) Subject Expert Committee (SEC) granted the EUA. The Science and Technology Ministry statement said: "Zydus Cadila has received approval for Emergency Use Authorisation (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D today."ZyCoV-D is a first of its kind DNA vaccine that produces the spike protein of the SARS-CoV-2 to elicit an immune response. It is an intradermal vaccine that has to be applied using a 'needle-free injector', which, the manufacturer says, will help in reducing side effects.Developed in partnership with the Department of Biotechnology, under 'Mission COVID Suraksha' and implemented by the BIRAC, ZyCoV-D has been supported under Covid-19 Research Consortia through National Biopharma Mission for Preclinical Studies, Phase 1 and Phase 2 Clinical Trials and under the Mission COVID Suraksha for Phase 3 Clinical Trial. This 3-dose vaccine, when injected, produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from disease as well as viral clearance. The plug-and-play technology on which the plasmid DNA platform is based can be easily adapted to deal with mutations in the virus, such as those already occurring.The interim results from Phase 3 Clinical Trials, involving over 28,000 volunteers, showed primary efficacy of 66.6 per cent for symptomatic RT-PCR positive cases. This has been the largest trial so far in India for Covid-19 vaccines.The vaccine had already exhibited robust immunogenicity and tolerability and safety profile in the adaptive Phase 1/2 clinical trials carried out earlier. The Phase 1/2 and Phase 3 clinical trials have been monitored by an independent Data Safety Monitoring Board (DSMB).--IANSavr/vd
Mexico City, Aug 19 (IANS) Mexico has authorised the emergency use of the US-manufactured Moderna vaccine against Covid-19, the country's Undersecretary of Prevention and Health Promotion Hugo Lopez-Gatell said.The Mexican official confirmed on his Twitter account on Wednesday that the Federal Commission for the Protection against Health Risks "issued the authorisation for emergency use of the Moderna vaccine", reports Xinhua news agency."We have eight approved vaccines with this one, all safe, quality and effective," Lopez-Gatell said.Earlier, the Ministry of Health stated that as of Tuesday, 78,765,073 vaccine doses had been administered in the country.Mexico aims to immunise its residents through a national plan with an investment of about $1.6 billion.--IANSksk/
New York, Aug 18 (IANS) While diabetes, obesity and a history of smoking cigarettes are considered as risk factors for poorer Covid-19 outcomes, a new study claims that people with cannabis use disorder (CUD) may also be at increased risk.The research from the Washington University in St Louis used genetic epidemiological models to determine that genetic predisposition to CUD is related to risk for a severe reaction to Covid-19.Having genetic variants does not mean a person has CUD or that the person has used cannabis.But, comparing people with the variants to their Covid outcomes, the researchers found genetic liability for CUD accounted for up to 40 per cent of genetically influenced risk factors, such as body mass index (BMI) and diabetes, for a severe Covid-19 presentation.This association suggested that heavy and problematic cannabis use may represent a modifiable pathway to minimise severe Covid-19 presentations, the researchers explained, in the journal Biological Psychiatry: Global Open Access.The study point to two possible outcomes: That a predisposition to CUD and severe Covid-19 are due to a common biological mechanism, like inflammatory conditions causing individuals to develop worse symptoms of Covid-19 and/or dependence on cannabis; or that they are associated because of a causal process, said Alexander S. Hatoum, a postdoctoral researcher at the varsity."If we know the genes that predispose individuals to cannabis use disorder, and if cannabis use disorder is a risk factor for Covid-19 hospitalisation, you will see the genes influencing cannabis use disorder as predictors of severe Covid-19 cases," he said."We found that a person's genetic risk for cannabis use disorder is correlated with their risk for Covid-19, without having to ask directly about illegal substance use," he added.For the study, the team combined existing datasets to test whether being at higher genetic risk for cannabis use disorder was correlated to the risk of Covid hospitalisation.One set of data involved 357,806 people, including 14,080 with CUD; the other involved 1,206,629 people, including 9,373 who were hospitalised with Covid. They also looked at 7 million genetic variants to assess the association between CUD and severe Covid.--IANSrvt/vd
New York, July 31 (IANS) A team of researchers has leveraged two new molecules, one of which is currently in clinical oncology trials, to devise a dual-drug therapy for alcohol use disorder (AUD), without the side-effects or complications associated with current treatment regimens.The study, published in the journal Nature Communications, indicates that the approach had highly successful results in mice and may apply to other drugs that are often abused."Alcohol use disorder is really a process of maladapted learning and memory," said researcher Dorit Ron from the University of California, San Francisco."Alcohol is rewarding, and we learn to associate alcohol, and even the environment in which we drink the alcohol, with that reward," Ron added.At the root of the team's thinking is the idea that AUD and other substance abuse disorders are the results of reinforced pathways in the brain, and that those pathways can be blocked or redirected, ending cravings and habitual behaviour.The researcher said she is studying the role of the enzyme mTORC1 in the creation of those memories and associations, to create an effective drug that can treat the neurological causes of AUD.Ordinarily, mTORC1 is involved in brain plasticity, helping to create connections between neurons that reinforce memory. In previous work, Ron showed that consuming alcohol activates the enzyme in the brain.Ron has also shown that blocking the activity of mTORC1 with the FDA-approved compound rapamycin, used to treat some types of cancer and suppress the immune response in transplant patients, can halt cravings in mice engineered for alcohol use disorder.But mTORC1 contributes to a bevy of other bodily tasks related to metabolism and liver function, and people taking it for an extended period often develop liver toxicity, glucose intolerance, and other side effects.Ron believes that tackling addiction from a neurological perspective has potential for broad applications."We could see these side effects in mice who are taking rapamycin or RapaLink-1, and then when you give Rapablock, it's like magic, the side effects are gone," Ron noted.--IANSvc/arm
Tokyo, July 30 (IANS) A Japanese Health Ministry panel on Friday approved the domestic use of the AstraZeneca Covid-19 vaccine for people aged 40 and above in principle due to a supply shortage of jabs.The federal government will supply the vaccine to local authorities depending on their demand, with a schedule for safety research, possibly conducted by Self-Defense Forces personnel, due to growing concerns over rare side effects, reports Xinhua news agency.The Ministry of Health, Labour and Welfare had sped up the approval for the AstraZeneca vaccine in May, but the government delayed supplying the doses, because of concerns on reported rare cases of blood clots among the young overseas.Japan's inoculation program currently utilises vaccines developed by US pharmaceutical companies Pfizer Inc. and Moderna Inc.Also on Friday, the Ministry panel approved extending the eligible age range for the Moderna vaccine from people aged 18 and older to those aged 12 years and older.The Moderna jab had been used in vaccination programs at workplaces but hit a supply bottleneck, and the central government's supplies of the Pfizer vaccine have failed to meet the speed of local governments' inoculations.--IANSksk/
Dear Patron, Please provide additional information to validate your profile and continue to participate in engagement activities and purchase medicine.